Skip to main content

Table 4 Expression of typical DC surface markers

From: Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

  CD14 CD40 CD80 CD83
% positive cells HD AML HD AML HD AML HD AML
C 1 ± 1 0 ± 0 100 ± 0 99 ± 1 100 ± 0 98 ± 3 100 ± 0 100 ± 0
CP 3 ± 4 2 ± 4 99 ± 1 97 ± 9 99 ± 1 98 ± 4 97 ± 9 95 ± 10
R 0 ± 0 1 ± 1 100 ± 0 90 ± 15 100 ± 0 100 ± 0 100 ± 0 100 ± 0
RP 8 ± 9 1 ± 0 99 ± 2 90 ± 10 99 ± 2 100 ± 0 100 ± 1 100 ± 1
MFIs                         
C 2 ± 1 1 ± 1 22 ± 2 27 ± 1 108 ± 2 61 ± 4 41 ± 2 35 ± 2
CP 2 ± 1 2 ± 1 19 ± 1 15 ± 2 87 ± 2 55 ± 2 36 ± 2 27 ± 2
R 2 ± 1 2 ± 1 22 ± 2 12 ± 2 129 ± 1 73 ± 2 60 ± 1 39 ± 1
RP 3 ± 2 2 ± 1 33 ± 2 13 ± 2 98 ± 2 80 ± 2 43 ± 2 52 ± 1
  CD86 CD274 CCR7 HLA-DR
% positive cells HD AML HD AML HD AML HD AML
C 100 ± 0 94 ± 14 79 ± 44 78 ± 40 66 ± 37 71 ± 22 100 ± 0 100 ± 0
CP 100 ± 1 90 ± 25 99 ± 2 97 ± 5 76 ± 25 81 ± 14 100 ± 0 99 ± 2
R 100 ± 0 100 ± 0 84 ± 16 98 ± 3 66 ± 35 80 ± 13 89 ± 16 100 ± 0
RP 99 ± 1 100 ± 0 89 ± 11 99 ± 2 65 ± 33 73 ± 20 99 ± 1 100 ± 0
MFIs                         
C 87 ± 2 46 ± 5 10 ± 4 8 ± 3 5 ± 3 6 ± 2 278 ± 1 327 ± 1
CP 80 ± 2 49 ± 4 24 ± 1 17 ± 2 8 ± 3 18 ± 4 273 ± 1 171 ± 2
R 136 ± 1 96 ± 2 14 ± 2 23 ± 4 6 ± 2 7 ± 2 209 ± 2 223 ± 2
RP 92 ± 2 71 ± 3 12 ± 2 17 ± 1 6 ± 3 9 ± 2 540 ± 1 215 ± 2